An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Authors

  • Roman-Ulrich Müller
  • A. Lianne Messchendorp
  • Henrik Birn
  • Giovambattista Capasso
  • Emilie Cornec-Le Gall
  • Olivier Devuyst
  • Albertien van Eerde
  • Patrick Guirchoun
  • Tess Harris
  • Ewout J. Hoorn
  • Nine V.A.M. Knoers
  • Uwe Korst
  • Djalila Mekahli
  • Yannick Le Meur
  • Tom Nijenhuis
  • Albert C.M. Ong
  • John A. Sayer
  • Franz Schaefer
  • Aude Servais
  • Vladimir Tesar
  • Roser Torra
  • Stephen B. Walsh and Ron T. Gansevoort

DOI:

https://doi.org/10.22141/2307-1257.11.1.2022.357

Abstract

No abstract

Downloads

Download data is not yet available.

Published

2022-05-24

How to Cite

Müller, R.-U., Lianne Messchendorp, A., Birn, H., Capasso, G., Cornec-Le Gall, E., Devuyst, O., Eerde, A. van, Guirchoun, P., Harris, T., Hoorn, E. J., Knoers, N. V., Korst, U., Mekahli, D., Le Meur, Y., Nijenhuis, T., Ong, A. C., Sayer, J. A., Schaefer, F., Servais, A., Tesar, V., Torra, R., & Gansevoort, S. B. W. and R. T. (2022). An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. KIDNEYS, 11(1), 37–39. https://doi.org/10.22141/2307-1257.11.1.2022.357

Issue

Section

Guidelines